arrow
Y

Yuki Tahata

University of Osaka
H指数:18
被引数:1,124

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All-Cause Mortality After SVR in Advanced Chronic Hepatitis C

血清缺乳糖基 IgG 预测晚期慢性丙型肝炎患者实现 SVR 后的肝细胞癌及全因死亡率

2026-09-070
OAAI
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

不可切除肝细胞癌中,比较一线阿替利珠单抗联合贝伐珠单抗后,二线度鲁特韦联合特瑞普利单抗与伦伐替尼的疗效比较

2026-05-070
OA
On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years

核苷(酸)类似物治疗>10年的患者中,治疗期间病毒因素影响后续乙型肝炎表面抗原血清清除

2026-04-210
OA
Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

抗凝治疗反应对肝硬化合并门静脉血栓患者肝脏相关事件的影响

2026-03-010
OAAI
Activation of the Integrin αV-YAP-CTGF Axis in Liver Sinusoidal Endothelial Cells Promotes Liver Fibrogenesis, Leading to Portal Hypertension and Liver Carcinogenesis in Congestive Hepatopathy

肝窦内皮细胞中整合素αV-YAP-CTGF轴的激活促进肝纤维化,导致充血性肝病的门静脉高压和肝致癌作用。

2026-02-270
OAAI
Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy

慢性丙型肝炎病毒感染患者直接抗病毒治疗后,血清CXCL10水平治疗后与治疗前的比值可预测代偿期和失代偿期肝硬化患者的短期肝功能结局

2026-02-010
OAAI
Guidance for Liver Rehabilitation in Chronic Liver Disease

慢性肝病肝脏康复指导

2026-01-310
OAAI
Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage

FDA批准药物库筛选鉴定的奥拉瑞芬通过溶酶体损伤抑制HBs抗原分泌

2026-01-160
PRE
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma

NRF2-COX2-PGE2轴驱动免疫冷肿瘤并预测肝细胞癌对联合免疫治疗的耐药性

2026-01-012
PRE
LSECs promote MASH progression via IL-1R1-mediated chemokine production induced by macrophage-derived IL-1β

肝窦内皮细胞(LSECs)通过巨噬细胞来源的IL-1β诱导的IL-1R1介导的趋化因子产生促进MASH进展。

2025-12-020
OAAI
Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial

直接抗病毒药物治疗后,丙型肝炎病毒相关失代偿性肝硬化患者肝脏储备功能和预后的长期变化:一项日本III期试验的五年随访研究

2025-10-300
PRE
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma

不可切除肝细胞癌中,阿替利珠单抗联合贝伐珠单抗后使用乐伐替尼与乐伐替尼作为一线治疗的比较分析

2025-10-250
PRE
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

血清生长分化因子15可作为预测丙型肝炎病毒肝硬化患者病毒清除后预后的新型生物标志物

2025-09-180
OAAI
Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

高血压作为潜在影响不可切除肝细胞癌患者阿替利珠单抗联合贝伐珠单抗治疗疗效的不良事件

2025-09-011
OAAI
Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy

治疗后血清CXCL10水平可对慢性丙型肝炎病毒感染导致的代偿期和失代偿期肝硬化患者的生存情况进行分层,尤其是在直接抗病毒治疗后。

2025-07-010
PRE
Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis

治疗前血清血管生成素-2可预测接受索磷布韦和韦帕他韦成功清除HCV后,HCV相关失代偿期肝硬化患者的预后及肝脏功能储备

2025-06-200
PRE
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy
2024-10-290
OAAI
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
2024-09-180
OAAI